Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Glucagon575 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A05959 | 33061687 | Hepat Med | Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review. | 2020 | Details |
| A06005 | 33039693 | Contemp Clin Trials | Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. | 2020 | Details |
| A06026 | 33036179 | J Clin Med | One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. | 2020 | Details |
| A06074 | 33015726 | Curr Diab Rep | Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06087 | 33011499 | Diabetes Metab Syndr | Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. | 2020 | Details |
| A06114 | 33001570 | Diabetes Obes Metab | Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice. | 2020 | Details |
| A06147 | 32987188 | Mol Metab | Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. | 2020 | Details |
| A06217 | 32964201 | JHEP Rep | The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. | 2020 | Details |
| A06230 | 32961563 | Exp Clin Endocrinol Diabetes | Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model. | 2020 | Details |
| A06232 | 32961235 | Life Sci | Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice. | 2020 | Details |
| A06246 | 32952876 | World J Hepatol | Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. | 2020 | Details |
| A06274 | 32945071 | Diabetes Obes Metab | A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? | 2020 | Details |
| A06297 | 32937194 | Mol Metab | Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. | 2020 | Details |
| A06320 | 32930541 | Eur J Histochem | β-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet. | 2020 | Details |
| A06367 | 32912770 | Dig Liver Dis | Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. | 2020 | Details |
| A06373 | 32909011 | medRxiv | Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. | 2020 | Details |
| A06467 | 32868684 | Curr Opin Clin Nutr Metab Care | Dietary protein intake and obesity-associated cardiometabolic function. | 2020 | Details |
| A06475 | 32865597 | Diabetologia | Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). | 2020 | Details |
| A06520 | 32843283 | J Diabetes Complications | Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. | 2020 | Details |
| A06675 | 32785012 | Int J Mol Sci | Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A06717 | 32771373 | Peptides | Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway. | 2020 | Details |
| A06735 | 32765720 | Exp Ther Med | Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). | 2020 | Details |
| A06861 | 32719069 | J Pharmacol Exp Ther | The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. | 2020 | Details |
| A06882 | 32711187 | Transl Res | The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. | 2020 | Details |
| A06901 | 32704576 | Endocrinol Diabetes Metab | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. | 2020 | Details |
| A06964 | 32684985 | Diabetol Metab Syndr | NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. | 2020 | Details |
| A06993 | 32668632 | Int J Mol Sci | Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? | 2020 | Details |
| A07111 | 32619031 | Diabet Med | Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. | 2020 | Details |
| A07117 | 32616276 | Can J Diabetes | Liver Stiffness Is Associated With Progression of Albuminuria in Adults With Type 2 Diabetes: Nonalcoholic Fatty Disease Cohort Study. | 2020 | Details |
| A07241 | 32571083 | Ann Pharmacother | A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A07299 | 32550751 | World J Gastroenterol | Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. | 2020 | Details |
| A07422 | 32506830 | J Diabetes Investig | Glucagon regulates lipolysis and fatty acid oxidation through inositol triphosphate receptor 1 in the liver. | 2020 | Details |
| A07430 | 32502637 | Pharmacol Res | Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. | 2020 | Details |
| A07440 | 32496108 | Rev Esp Enferm Dig | The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A07480 | 32478287 | Nat Metab | Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. | 2020 | Details |
| A07629 | 32414752 | BMJ Open Gastroenterol | Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis. | 2020 | Details |
| A07726 | 32375182 | Horm Metab Res | Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells. | 2020 | Details |
| A07888 | 32322207 | Front Pharmacol | Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. | 2020 | Details |
| A07979 | 32291277 | Diabetes Care | Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. | 2020 | Details |
| A08033 | 32274915 | Minerva Pediatr | Metabolic syndrome in children. | 2020 | Details |
| A08062 | 32259637 | Mol Cell Endocrinol | Anti-steatotic linagliptin pleiotropic effects encompasses suppression of de novo lipogenesis and ER stress in high-fat-fed mice. | 2020 | Details |
| A08109 | 32244182 | Mol Metab | Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice. | 2020 | Details |
| A08113 | 32243137 | Bioconjug Chem | New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice. | 2020 | Details |
| A08128 | 32237916 | Expert Opin Pharmacother | Current and new pharmacotherapy options for non-alcoholic steatohepatitis. | 2020 | Details |
| A08139 | 32231442 | Clin Med Insights Endocrinol Diabetes | Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism. | 2020 | Details |
| A08155 | 32225108 | Int J Mol Sci | Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH). | 2020 | Details |
| A08219 | 32196896 | Diabetes Obes Metab | Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. | 2020 | Details |
| A08267 | 32180556 | Mol Metab | Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. | 2020 | Details |
| A08276 | 32171530 | Biochem Biophys Res Commun | Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway. | 2020 | Details |
| A08288 | 32168769 | Int J Mol Sci | Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08296 | 32165250 | J Hepatol | Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. | 2020 | Details |
| A08318 | 32153507 | Front Endocrinol (Lausanne) | Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. | 2020 | Details |
| A08341 | 32147363 | J Hepatol | Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A. | 2020 | Details |
| A08344 | 32147318 | Peptides | Glucagon-based therapy: Past, present and future. | 2020 | Details |
| A08382 | 32132708 | Nature | Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis. | 2020 | Details |
| A08511 | 32081018 | Rev Esp Enferm Dig | Mechanism of bariatric and metabolic surgery: beyond surgeons, gastroenterologists and endocrinologists. | 2020 | Details |
| A08665 | 32028458 | Med Sci Sports Exerc | Exercise Training Rapidly Increases Hepatic Insulin Extraction in NAFLD. | 2020 | Details |
| A08701 | 32017891 | Am J Med | Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? | 2020 | Details |
| A08840 | 31969650 | Sci Rep | Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. | 2020 | Details |
| A08867 | 31956961 | Diabetes Ther | Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08872 | 31955491 | Diabetes Metab Res Rev | Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. | 2020 | Details |
| A08963 | 31923578 | Diabetes Metab | Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. | 2020 | Details |
| A09047 | 31889754 | J Clin Exp Hepatol | Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09108 | 31870938 | Peptides | Endogenously released GIP reduces and GLP-1 increases hepatic insulin extraction. | 2019 | Details |
| A09257 | 31815784 | Curr Opin Endocrinol Diabetes Obes | Gastrointestinal peptides and nonalcoholic fatty liver disease. | 2020 | Details |
| A09333 | 31787541 | Ann Hepatol | The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy. | 2019 | Details |
| A09402 | 31759125 | Peptides | The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). | 2019 | Details |
| A09415 | 31757735 | Presse Med | [Pharmacological treatment of NASH]. | 2019 | Details |
| A09573 | 31690988 | Diabetologia | Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. | 2019 | Details |
| A09574 | 31690932 | J Clin Endocrinol Metab | Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. | 2020 | Details |
| A09614 | 31673703 | Endocrinology | Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression. | 2020 | Details |
| A09620 | 31672448 | Metabolism | Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! | 2019 | Details |
| A09736 | 31631098 | Endocr J | Regulation of angiopoietin-like protein 8 expression under different nutritional and metabolic status. | 2019 | Details |
| A09758 | 31622581 | Am J Med | Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09759 | 31622202 | Curr Drug Deliv | Protective Effects of Incretin Against Age-Related Diseases. | 2019 | Details |
| A09842 | 31593687 | Eur J Pharmacol | Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. | 2019 | Details |
| A09930 | 31555865 | Pediatr Surg Int | Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome. | 2019 | Details |
| A10238 | 31418344 | Curr Vasc Pharmacol | What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? | 2019 | Details |
| A10249 | 31412267 | Eur J Pharmacol | Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. | 2019 | Details |
| A10314 | 31389309 | Thyroid | Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. | 2019 | Details |
| A10333 | 31386258 | Liver Int | Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion. | 2019 | Details |
| A10476 | 31321014 | Ther Adv Chronic Dis | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. | 2019 | Details |
| A10507 | 31308717 | Diabetes Metab Syndr Obes | Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway. | 2019 | Details |
| A10508 | 31308716 | Diabetes Metab Syndr Obes | SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. | 2019 | Details |
| A10662 | 31246368 | Aliment Pharmacol Ther | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. | 2019 | Details |
| A10676 | 31241045 | Gen Physiol Biophys | Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers. | 2019 | Details |
| A10687 | 31236111 | Int J Endocrinol | Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway. | 2019 | Details |
| A10807 | 31180545 | Mol Med Rep | LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet. | 2019 | Details |
| A10891 | 31137547 | Medicina (Kaunas) | Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10934 | 31114547 | Front Endocrinol (Lausanne) | Hepatic Gene Expression Profiles Differentiate Steatotic and Non-steatotic Grafts in Liver Transplant Recipients. | 2019 | Details |
| A10989 | 31089576 | J Obes Metab Syndr | The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. | 2019 | Details |
| A11010 | 31082799 | J Endocrinol | Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. | 2019 | Details |
| A11071 | 31058888 | J Vis Exp | Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution. | 2019 | Details |
| A11125 | 31031702 | Front Endocrinol (Lausanne) | The Discovery and Development of Liraglutide and Semaglutide. | 2019 | Details |
| A11209 | 30998190 | Ann Biol Clin (Paris) | [Incretins-adipocytokines interactions in type 2 diabetic subjects with or without non-alcoholic fatty liver disease: interest of GLP-1 (glucagon-like peptide-1) as a modulating biomarker]. | 2019 | Details |
| A11210 | 30995792 | Int J Mol Sci | Glucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism. | 2019 | Details |
| A11279 | 30961499 | Curr Vasc Pharmacol | Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. | 2020 | Details |
| A11310 | 30945129 | Curr Obes Rep | Nonalcoholic Fatty Liver Disease and Obesity Treatment. | 2019 | Details |
| A11366 | 30920583 | Endocr Rev | The Liver-α-Cell Axis and Type 2 Diabetes. | 2019 | Details |
| A11413 | 30905315 | Adipocyte | Adipocytes as lipid sensors of oleic acid transport through a functional Caco-2/HT29-MTX intestinal barrier. | 2019 | Details |